Prana’s COO Diane Angus, Head Of Research Robert Cherny On Prana’s Unique Mechanism Of Action In Neurodegenerative Drug Development: An Interview With PharmAsia News (Part 2 of 2)

Established in 1997, Melbourne, Australia-based biotech company Prana has developed a library of chemical compounds that addresses the role of biological metals in human disease. The company's lead compound PB2 in Alzheimer's disease completed Phase IIa clinical trials, and the company recently announced a preclinical candidate for Parkinson's disease. "Prana" is Sanskrit for "moving force," or "life force," which sustains life and diminishes as humans age. The company has formed its business strategy on neurological disorders that result from interactions between selected metals and target proteins as the brain ages. COO Diane Angus and Head of Research Robert Cherny sat down with PharmAsia News in Australia to talk about Prana's unique approach to developing compounds in the neurodegenerative space.